Zinzani, P. L. Et Al. 2022. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances , vol.6, no.2 , 590-599.

Zinzani, P. L., Ramchandren, R., Santoro, A., Paszkiewicz-Kozik, E., Gasiorowski, R., Johnson, N. A., ... de Oliveira, J. S.(2022). Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Advances , vol.6, no.2, 590-599.

Zinzani, Pier Et Al. "Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma," Blood Advances , vol.6, no.2, 590-599, 2022

Zinzani, Pier L. Et Al. "Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma." Blood Advances , vol.6, no.2, pp.590-599, 2022

Zinzani, P. L. Et Al. (2022) . "Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma." Blood Advances , vol.6, no.2, pp.590-599.

@article{article, author={Pier Luigi Zinzani Et Al. }, title={Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma}, journal={Blood Advances}, year=2022, pages={590-599} }